BACKGROUND: Cutaneous leishmaniasis (CL) represents a range of skin diseases caused by infection with Leishmania parasites and associated with tissue inflammation and skin ulceration. CL is clinically widespread in both the Old and New World but lacks treatments that are well tolerated, effective and inexpensive. Oleylphosphocholine (OlPC) is a new orally bioavailable drug of the alkylphosphocholine family with potent antileishmanial activity against a broad range of Leishmania species/strains. METHODOLOGY/PRINCIPAL FINDINGS: The potential of OlPC against Old World CL was evaluated in a mouse model of Leishmania (L.) major infection in BALB/c mice. Initial dose-response experiments showed that an oral daily dose of 40 mg/kg of OlPC was needed to impact time to cure and lesion sizes. This dose was then used to directly compare the efficacy of OlPC to the efficacy of the antileishmanial drugs miltefosine (40 mg/kg/day), fluconazole (160 mg/kg/day) and amphotericin B (25 mg/kg/day). OlPC, miltefosine and fluconazole were given orally for 21 days while amphotericin B was administered intraperitoneally for 10 days. Ulcer sizes and animal weights were followed up on a weekly basis and parasitemia was determined by means of a real-time in vivo imaging system which detects luminescence emitted from luciferase-expressing infecting L. major parasites. Amphotericin B and OlPC showed excellent efficacy against L. major lesions in terms of reduction of parasitic loads and by inducing complete healing of established lesions. In contrast, treatment with miltefosine did not significantly affect parasitemia and lesion sizes, while fluconazole was completely ineffective at the dose regimen tested. CONCLUSIONS/SIGNIFICANCE: Given the data showing the outstanding efficacy and tolerability of OlPC, our results suggest that OlPC is a promising new drug candidate to improve and simplify current clinical management of L. major CL.
BACKGROUND:Cutaneous leishmaniasis (CL) represents a range of skin diseases caused by infection with Leishmania parasites and associated with tissue inflammation and skin ulceration. CL is clinically widespread in both the Old and New World but lacks treatments that are well tolerated, effective and inexpensive. Oleylphosphocholine (OlPC) is a new orally bioavailable drug of the alkylphosphocholine family with potent antileishmanial activity against a broad range of Leishmania species/strains. METHODOLOGY/PRINCIPAL FINDINGS: The potential of OlPC against Old World CL was evaluated in a mouse model of Leishmania (L.) majorinfection in BALB/c mice. Initial dose-response experiments showed that an oral daily dose of 40 mg/kg of OlPC was needed to impact time to cure and lesion sizes. This dose was then used to directly compare the efficacy of OlPC to the efficacy of the antileishmanial drugs miltefosine (40 mg/kg/day), fluconazole (160 mg/kg/day) and amphotericin B (25 mg/kg/day). OlPC, miltefosine and fluconazole were given orally for 21 days while amphotericin B was administered intraperitoneally for 10 days. Ulcer sizes and animal weights were followed up on a weekly basis and parasitemia was determined by means of a real-time in vivo imaging system which detects luminescence emitted from luciferase-expressing infecting L. major parasites. Amphotericin B and OlPC showed excellent efficacy against L. major lesions in terms of reduction of parasitic loads and by inducing complete healing of established lesions. In contrast, treatment with miltefosine did not significantly affect parasitemia and lesion sizes, while fluconazole was completely ineffective at the dose regimen tested. CONCLUSIONS/SIGNIFICANCE: Given the data showing the outstanding efficacy and tolerability of OlPC, our results suggest that OlPC is a promising new drug candidate to improve and simplify current clinical management of L. major CL.
Authors: Anastácio Q Sousa; Mércia S Frutuoso; Elisabete A Moraes; Richard D Pearson; Margarida M L Pompeu Journal: Clin Infect Dis Date: 2011-10 Impact factor: 9.079
Authors: Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró Journal: Parasitol Res Date: 2013-11-06 Impact factor: 2.289
Authors: Eva Iniguez; Armando Varela-Ramirez; Alberto Martínez; Caresse L Torres; Roberto A Sánchez-Delgado; Rosa A Maldonado Journal: Acta Trop Date: 2016-09-30 Impact factor: 3.112
Authors: Felipe Rodriguez; Sarah F John; Eva Iniguez; Sebastian Montalvo; Karina Michael; Lyndsey White; Dong Liang; Omonike A Olaleye; Rosa A Maldonado Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191
Authors: Andrew A Voak; Andy Harris; Jose Miguel Coteron-Lopez; Iñigo Angulo-Barturen; Santiago Ferrer-Bazaga; Simon L Croft; Karin Seifert Journal: PLoS Negl Trop Dis Date: 2021-03-02
Authors: Eva Iniguez; Nathaniel S Schocker; Krishanthi Subramaniam; Susana Portillo; Alba L Montoya; Waleed S Al-Salem; Caresse L Torres; Felipe Rodriguez; Otacilio C Moreira; Alvaro Acosta-Serrano; Katja Michael; Igor C Almeida; Rosa A Maldonado Journal: PLoS Negl Trop Dis Date: 2017-10-25
Authors: Karine Sonzogni-Desautels; Axel E Renteria; Fabio V Camargo; Thomas Z Di Lenardo; Alexandre Mikhail; Michael J Arrowood; Anny Fortin; Momar Ndao Journal: Front Microbiol Date: 2015-09-23 Impact factor: 5.640